Hetero Labs generic will be sold under the name Covifor and will cost between $66 and $79 for a 100 milligram dose, the drugmaker said.
The Cipla generic will be sold under the name Cipremi.
“Cipla appreciates the strong partnership with Gilead to bring remdesivir to patients in India. We have been deeply invested in exploring all possible avenues to save millions of lives impacted by COVID-19 pandemic, and this launch is a significant milestone in that direction,” said Umang Vohra, MD, CEO of Cipla.
In May, Gilead Sciences signed a licensing agreement with five generic drugmakers to expand remdesivir production and make it available in 127 countries.
Mylan, Cipla, Ferozsons Laboratories, Hetero and Jubilant Life Sciences will make remdesivir for distribution, Gilead said in May.
More articles on pharmacy:
Kaiser Permanente joins Civica Rx to supply generic drugs
Nearly 90% of Americans worried about drug price hikes
FTC didn’t follow its own rules in OK of Allergan takeover, California says
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
